Clinical Trial Translation Requirements: Documents, Validation and QA
Clinical trial translation requirements depend on the country, regulatory route, ethics-review process, trial population and document type. Participant-facing materials must be understandable to the people who receive them, while regulatory and operational documents may follow different language rules. This guide explains the main document groups, EU and U.S. principles, validation methods and quality checks that should be considered before translated trial materials are submitted or used.
Start with the jurisdiction and the audience
Clinical trial translation is not governed by one global language rule. Sponsors need to determine which documents require translation in each country and which language or languages are accepted by the relevant competent authority, ethics committee or institutional review board.
Regulatory audience
Application dossiers, protocols and supporting documents may be subject to authority- or country-specific language rules.
Participant audience
Participant-facing information should be understandable to the population expected to receive and use it.
Site and operational audience
Site manuals, training materials and operational documents may need localization according to site staff needs and sponsor procedures.
EU clinical trial language requirements are Member State-specific
Article 26 of Regulation (EU) No 536/2014 provides that the language of the clinical trial application dossier, or parts of it, is determined by the Member State concerned.
Current European Commission guidance therefore includes Member State-specific language requirements. Sponsors should check the latest Clinical Trials Regulation Q&A and national requirements before preparing translated Part I or Part II material for CTIS.
Informed consent information must be understandable to the participant
Under 21 CFR 50.20, information given to a clinical trial participant or legally authorized representative must be in language understandable to that person.
FDA guidance also explains that when an IRB anticipates consent interviews in a language other than English, it should assure that a translated consent form is prepared and that the translation is accurate.
ICH E6(R3) emphasises understandable informed consent information
ICH E6(R3), finalised in 2025, states that informed consent information should be as clear and concise as possible, use simple language and enable potential participants or their legally acceptable representatives to understand the trial well enough to make an informed decision.
Revised informed consent materials should also receive the required IRB/IEC approval or favourable opinion before use where re-consent is needed.
Which clinical trial documents may require translation?
The exact set depends on the trial and jurisdiction, but multilingual studies commonly involve several distinct document groups.
Regulatory documents
Protocols, summaries, investigator documentation, application materials and authority correspondence where local language rules apply.
Participant documents
Informed consent, participant information, assent, recruitment materials and participant communications.
Clinical outcome instruments
Questionnaires, diaries, scales, ePRO content and other instruments that may require controlled translation or linguistic validation.
Site and operational documents
Manuals, training materials, pharmacy instructions, device instructions and site communications.
Informed consent translation requires both accuracy and readability
Participant-facing consent materials have a different purpose from technical regulatory documents. They need to preserve the approved meaning while remaining understandable to the target participant population.
Overly literal translation can preserve individual words while making the final consent document harder to understand. The translation should therefore protect the source meaning, risk information, rights and procedures without introducing new claims.
Translation validation should match the document type and risk
“Validation” can mean different things in clinical research. A high-risk participant instrument may use a formal linguistic-validation methodology, while an operational document may use translation plus independent review and documented QA.
Forward translation
Translation from the source language into the target language by a qualified translator.
Reconciliation
Comparison and consolidation of translation choices where multiple forward versions are used.
Back translation
Translation of the target text back into the source language as a review tool where the chosen methodology calls for it.
Cognitive debriefing
Testing whether members of the target population understand an instrument as intended, where required by the instrument methodology.
Keep terminology consistent across the complete trial
The same investigational product, procedure, endpoint or medical concept can appear in the protocol, consent form, patient diary, investigator materials and safety communications.
A controlled terminology list reduces unnecessary variation and makes revisions easier to manage across documents and languages.
Every translation must match the correct approved source version
Clinical trial documents change throughout the study. Amendments, safety updates and revised consent forms can create several active versions in a short period.
Source version
Record the exact source document name, version number and date used for translation.
Target version
Make the translated version identifiable and traceable to its source.
Tracked changes
Process amendments carefully so additions, deletions and revised safety information are not missed.
Approval status
Do not confuse draft translations with versions approved for submission or participant use.
Check doses, units, visit schedules and numerical data carefully
Clinical trial documents contain many numbers that can affect participant safety or protocol compliance. Numerical QA should therefore be a separate part of the review process.
Doses
Verify dose values, units, frequency and route of administration against the source.
Visit schedules
Check visit numbers, windows, dates and time intervals carefully.
Laboratory values
Preserve values, ranges and units without accidental conversion or decimal changes.
Percentages and probabilities
Verify risk figures, percentages and statistical values exactly where they appear in participant or regulatory documents.
Clinical trial translation QA checklist
- The correct approved or designated source version was used.
- The target-language version is traceable to the source document.
- Required Member State, authority or IRB/IEC language rules have been checked.
- Participant-facing language is clear and understandable for the intended population.
- Trial terminology is consistent across related documents.
- Investigational product names and study identifiers are correct.
- Doses, units, percentages and visit schedules match the source.
- Safety information has not been weakened, omitted or expanded.
- Tables, headings, footnotes and cross-references are complete.
- Tracked changes and amendments have been processed correctly.
- Formatting and document structure have been reviewed after layout.
- The required translation or validation workflow has been documented.
- Draft and approved versions are clearly distinguished.
Clinical trial translation mistakes to avoid
Using the wrong source version
A linguistically correct translation of an obsolete consent form can still be unusable for the trial.
One workflow for every document
Regulatory documents, consent forms and clinical outcome instruments may require different review or validation methods.
Overly technical participant language
Participant-facing materials should remain understandable rather than reproducing protocol terminology mechanically.
No amendment control
New safety information or revised trial procedures can be lost if changes are not tracked across all language versions.
Clinical, medical and pharmaceutical translation services
Continue reading
Verify current requirements before submission or participant use
This guide provides general information and is not regulatory or legal advice. Clinical trial language and document requirements can change and should be checked for the actual study and jurisdiction.
Clinical Trial Translation Requirements — Frequently Asked Questions
Which clinical trial documents need translation?
There is no universal list that applies in every country and every trial. Translation requirements depend on the jurisdiction, Member State or authority, ethics committee or IRB requirements, target participant population and document type. Participant-facing materials commonly require language that participants can understand.
Do informed consent forms need to be translated?
When potential participants do not understand the source language, participant information and informed consent materials generally need to be available in language they can understand, subject to the applicable regulatory and ethics-review requirements.
Does every clinical trial document require back translation?
No. Back translation is not a universal requirement for every clinical trial document. The translation and validation method should be defined according to the document type, regulatory requirements, risk, sponsor procedures and any requirements for a specific instrument.
What is linguistic validation in clinical trials?
Linguistic validation is a structured process used to demonstrate that translated participant-facing instruments preserve the intended concepts and are understandable in the target population. It can involve forward translation, reconciliation, back translation, review and cognitive debriefing depending on the instrument and methodology.
What are the EU language requirements for clinical trial applications?
Under the EU Clinical Trials Regulation, the language of the application dossier or parts of it is determined by the Member State concerned. Current European Commission guidance provides Member State-specific language requirements, including for Part I documents.
What should be checked during clinical trial translation QA?
QA should cover version control, terminology, participant-facing language, numbers and units, medicinal product names, consistency across related documents, tables, references, tracked changes, formatting and confirmation that the translated version matches the approved source version.
Need clinical trial documents translated?
Send the document list, source and target languages, countries involved, current source versions and any sponsor, authority or ethics-committee requirements. We can review the translation scope, terminology, validation workflow and deadline before preparing a quote.